(Q39680458)

13 September 2017

The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors (English)

1 reference

13 September 2017

10

1 reference

13 September 2017

Sonja Mertsch

4

0 references

author name string

Björn Koos

1

1 reference

13 September 2017

Astrid Jeibmann

2

1 reference

13 September 2017

Henning Lünenbürger

3

1 reference

13 September 2017

Nina N Nupponen

5

1 reference

13 September 2017

Annariikka Roselli

6

1 reference

13 September 2017

Ivo Leuschner

7

1 reference

13 September 2017

Werner Paulus

8

1 reference

13 September 2017

Michael C Frühwald

9

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

13 September 2017

1 reference

13 September 2017

116

1 reference

13 September 2017

21

1 reference

13 September 2017

5075-5081

1 reference

Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor.

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

Oncogenic activation of c-ABL by mutation within its last exon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

NVP-BEZ235 as a new therapeutic option for sarcomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

PDGFRB is overexpressed in metastatic medulloblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Platelet-derived growth factor receptor expression and activation in choroid plexus tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

C-kit expression and mutational analysis in medulloblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

ABL1 amplification in T-cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25420

7 January 2021

Identifiers

DOI

10.1002/CNCR.25420

1 reference

13 September 2017

1 reference